Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denecimig (Mim8) in adults with acquired haemophilia A
2026-525529-19-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, open-label, single-arm trial of denecimig in acquired haemophilia (AH), sponsored by Novo Nordisk. Primary endpoint: Number of treated bleeds during main treatment period. Planned start Oct 2026; status: authorised.
02
Drugs
denecimig
03
Conditions
acquired haemophilia (AH)
Beyond the preview
Go deeper on 2026-525529-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525529-19-00.